Concepedia

Publication | Closed Access

Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

DOI

125

Citations

44

References

2018

Year

Priyanka Sharma, Sara López‐Tarruella, José Á. García-Sáenz, Qamar J. Khan, Henry Gómez, Aleix Prat, Fernando Moreno, Yolanda Jerez-Gilarranz, Agustí Barnadas, Antoni C. Picornell,
Clinical Cancer Research

Abstract

Neoadjuvant carboplatin plus docetaxel yields encouraging efficacy in TNBC. Patients achieving pCR or RCB I with this regimen demonstrate excellent 3-year RFS and OS without adjuvant anthracycline.

References

YearCitations

Page 1